Objective: To describe management strategies that contributed to optimal outcomes in pediatric recipients of a total pancreatectomy with islet autotransplantation (TPIAT). Research Design and Methods: We provide a comprehensive report of the approach to endocrine management of the pediatric TPIAT recipient from initial evaluation through the first 4 years postsurgery. We performed a retrospective review of the endocrine outcomes of TPIAT recipients to describe the impact of this approach on post-TPIAT glycemic management. Results: Outcome data from 86 TPIAT recipients were reviewed. At 12 months post-TPIAT (n = 82), the median HbA1C was 6.0% (25-75th percentile 5.6-6.7), at 18 months (n = 56) HbA1C was 6.4% (5.6-7.5), at 2 years (n = 46) HbA1C was 6.4% (5.6-7.4), at 3 years (n = 31) HbA1C was 6.5% (5.5-8.1), and at 4 years (n = 16) HbA1C was 7.2% (6.2-8.3). Conclusions: Pediatric patients at our institution have favorable endocrine outcomes as evidenced by median HbA1C under the goal of 6.5% through the initial 3 years by following our modified management protocols.

中文翻译：

---

一组接受胰岛自体移植全胰腺切除术的儿科患者的内分泌管理和临床结果。

目的：描述有助于全胰腺切除联合胰岛自体移植（TPIAT）儿科受者获得最佳结果的管理策略。研究设计和方法：我们提供了一份关于儿科 TPIAT 接受者从最初评估到术后 4 年内分泌管理方法的综合报告。我们对 TPIAT 接受者的内分泌结果进行了回顾性评价，以描述该方法对 TPIAT 后血糖管理的影响。结果：对 86 名 TPIAT 接受者的结果数据进行了审查。TPIAT 后 12 个月 (n = 82)，中位 HbA1C 为 6.0%（25-75 个百分位数 5.6-6.7），18 个月 (n = 56) 时，HbA1C 为 6.4% (5.6-7.5)，2 年（ n = 46) HbA1C 为 6.4% (5.6-7.4)，3 年时 (n = 31) HbA1C 为 6.5% (5.5-8.1)，4 年时 (n = 16) HbA1C 为 7.2% (6.2-8.3) 。结论：通过遵循我们修改后的管理方案，我们机构的儿科患者在最初 3 年中 HbA1C 中位数低于 6.5% 的目标，取得了良好的内分泌结果。